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Introduction
Epidermolysis bullosa (EB) is the term utilized to characterize a family of inherited blistering diseases.
1 EB subgroups are divided based on the level of blister formation within the skin, with location of the split found to correlate with the genetic lesion responsible for the underlying disorders. [2] [3] [4] [5] In the case of epidermolysis bullosa simplex, the plane of blister formation occurs in the most superficial location of EB subgroups, namely within the lower epidermis, and has been shown due to mutations in genes encoding basal keratins 5 and 14 6, 7 and more recently, plectin. 8 Abnormalities of protein components of the basement membrane zone are associated with a deeper split at the dermal-epidermal junction, producing the clinical disorders collectively known as junctional epidermolysis bullosa (JEB). Proteins encoded by genes mutated in JEB include BP180 (type XVII collagen, BPAG2 or HD-4), 9 Laminin 5 ␣3, ␤3 and ␥2 chains 10, 11 and integrins ␣6 and ␤4. [12] [13] [14] Deeper blisters occurring below the level of those seen in JEB characterize a group of patients afflicted with dystrophic EB have been found to be due to mutations in the type VII collagen gene. 15, 16 Because the proteins affected in EB are generally large structural proteins with multiple functional domains, small molecule pharmacotherapy has thus far been of little benefit. In contrast to the major advances in understanding the pathogenesis of these disorders, progress in the treatment of EB patients has been minimal and current therapy is only supportive. With the molecular characterization of the underlying genetic defects responsible for these blistering disorders, the opportunity for the development of rational genetic therapies has arrived. COL17A1 encodes BP180 and is mutated in a subtype of JEB characterized by a generally non-lethal clinical course with blisters that heal leaving atrophic skin changes.
9 BP180 is also involved in the pathogenesis of the autoimmune blistering disease, bullous pemphigoid, 17 in which patient autoantibodies are generated against BP180. BP180 is a collagenous transmembrane type II protein component of the hemidesmosome [18] [19] [20] involved in adhesion of the epidermis to the underlying dermis. [21] [22] [23] The size and multiple domains of this protein pose major barriers to developing effective conventional pharmacologic therapy for BP180-deficient JEB. Therapeutic gene delivery is a general approach being developed in a wide range of tissues and the skin is an attractive tissue for this technology by virtue of its accessibility and by the existence of such well-characterized monogenic recessive diseases to serve as human disease model prototypes. Development of gene therapy for EB requires establishment of models of restorative gene delivery. In order to achieve this, we transduced early passage keratinocytes from BP180-deficient JEB patients with a retroviral expression vector for wild-type human BP180. BP180 gene transfer results in improvement of functional defects in JEB cell adhesion in vitro, as well as restores expression of BP180 protein at the basement membrane zone in JEB skin regenerated in vivo.
Results

BP180 gene transfer to BP180-negative JEB keratinocytes
In order to develop a model of gene delivery in EB we produced an amphotropic retroviral expression vector for human BP180 (Figure 1a ). This vector was used to transduce primary keratinocytes from two patients with generalized atrophic benign EB. The patients in this study lack BP180 protein expression but express normal levels of other cutaneous basement membrane zone proteins, including laminin 5 and ␣6␤4 integrin. The patient whose cells were used for in vivo experiments has also been confirmed to have mutations in both BP180 alleles (Marinkovich MP et al, unpublished) . Untransduced JEB cells demonstrated no full-length BP180 protein expression as detected by a panel of monoclonal and polyclonal antibodies to human BP180. JEB cells transduced with this vector, however, demonstrated full-length BP180 in amounts comparable to that seen in normal cells (Figure 1b) , with similar results obtained in cells from both patients.
Effect of BP180 gene transfer on cellular adhesion in vitro To determine if BP180 gene transfer exerts a functional effect on JEB cells, we performed an in vitro assay of the central function in which these cells are defective, adhesion. Defective adhesive properties, believed responsible for the clinical blistering seen in JEB patients, can be readily measured in JEB cells in vitro. 24 We performed a trypsinization assay to determine the kinetics of cell dissociation from a tissue culture substrate. BP180 gene transfer is associated with a restoration of dissociation kinetics to normal levels (Figure 2a) , suggesting a functional correction of this abnormality. Regeneration of JEB skin tissue in vivo on immunedeficient mice After restoring BP180 expression to JEB cells and identifying evidence of a corrective functional effect in vitro, we wished to determine if such genetically engineered early passage cells could be useful in BP180 gene delivery in vivo. To do this, we established an in vivo human tissue model of BP180-negative JEB. Transduced and untreated JEB patient cells, along with normal controls, were used to regenerate human skin tissue on immunodeficient mice. 25, 26 Untreated JEB cell grafts did not demonstrate frank evidence of clinical blistering. Four weeks after the operation, skin tissue was excised and analyzed. Both transduced and untransduced JEB cells regenerated skin with a histologic appearance similar to that produced by normal controls (Figure 3a and b) . However, a subepidermal blister was detected histologically in one skin tissue graft regenerated from untransduced JEB cells (Figure 3c ) in a pattern similar to that seen commonly in regenerating subepidermal blisters. 27 Such histologic evidence of blistering was not observed in any of the stepwise tissue sections from normal controls or from JEB skin regenerated after BP180 gene transfer in this study and has also not been observed in analysis of normal control human grafts generated by similar methods in previous studies. 28 The human species origin, as well as the expression of basement membrane components other than BP180, was confirmed by immunostaining with species-specific antibodies for human laminin 5 ␤3 chain (Figure 3d-f) . 29 Restoration of BP180 expression to regenerated JEB skin in vivo To determine if BP180 gene transfer in vitro before grafting could lead to restored BP180 expression in vivo, immunostaining was performed with antibodies to BP180 on regenerated human skin tissue specimens. At 4 weeks after grafting, untransduced cells regenerated human epidermis that entirely lacked BP180 protein expression, as expected. BP180 vector-transduced JEB cells, however, demonstrated restoration of BP180 expression in the cor- 
Discussion
Defects in the basal layer program of epidermal gene expression lead to a number of inherited blistering diseases, including JEB. Following identification of relevant disease genes, the development of rational genetic therapies may require progression through a series of steps.
Figure 4 Restoration of BP180 expression to regenerated JEB skin in vivo. Immunofluorescence staining of regenerated JEB and control skin grafts was performed with antibodies specific for human BP180. (a,d) BP180[+], tissue regenerated from BP180-deficient primary JEB keratinocytes after BP180 gene transfer in vitro. (b,e) BP180[−], tissue regenerated from primary JEB keratinocytes from the same patient without previous BP180 gene transfer. (c,f) NL, normal control regenerated tissue from keratinocytes derived from patients without skin disease. Scale bars, 100 m for (a-c); and 25 m for (d-f).
Among the first of these is re-introduction of the relevant wild-type gene to patient cells in vitro, with transformed cell lines usually used initially, as has previously been achieved in cells immortalized from a patient with another EB subtype deficient in the laminin 5 ␥2 chain. 24 When effective gene transfer approaches have been developed, this work is extended to non-immortalized primary cells of the target tissue as we have done here. A related next step is demonstration of restored gene expression and correction of a measurable disease charac-teristic in primary patient cells in vitro. In the case of skin, such a demonstration is best followed by establishment of an in vivo model of restored gene expression for a given disease using the non-transformed cells and general approaches that are planned for eventual use in humans. These last two steps are the focus of the current work.
Here we have used gene transfer to JEB cells in order to restore expression of BP180, a protein component of hemidesmosomes necessary for normal dermal-epidermal cohesion. Immunostaining performed with human species-specific antibody to BP180 on adjacent mouse skin demonstrated no specific staining, therefore excluding the possibility that selective murine tissue ingrowth could account for the restoration of BP180 in JEB skin. To verify that other basement membrane zone components were present in unengineered BP180-negative JEB skin regenerated in vivo, we performed immunostaining with antibody to laminin 5, another important basement membrane zone protein that is affected in other types of JEB.
Patient and control specimens all demonstrated a normal laminin 5 expression pattern, indicating that the lack of BP180 expression in unengineered JEB skin recapitulates the disease picture seen in humans and is not due to a global failure of basement membrane zone component formation by BP180-negative cells in this model. These human species-specific antibodies to laminin 5 also provided further confirmation of the human origin of the analyzed tissue.
The JEB patient keratinocytes studied here regenerated human skin tissue with no clear clinical evidence of a blistering phenotype, however, subepidermal bulla formation was observed at the histologic level. The reason for a lack of clinical bullae is unclear, however, it may be explained by the fact that generalized atrophic JEB is characterized by significant areas of uninvolved skin and by a milder blistering phenotype than that seen in the severe Herlitz form. 1 In addition, our xenograft model may lack elements, such as adequate surface area or appropriate types of mechanical trauma, needed to recapitulate formation of clinically apparent blisters. BP180 protein is normally only expressed in the basement membrane zone by cells in the basal layer of stratified epithelia. In these studies, we used a retroviral promoter which is active in all layers of stratified epithelium, 30 however, we found this basal pattern of protein expression was maintained. This retention of basement membrane zone expression and the lack of evidence of suprabasal protein expression could point to the existence of mechanisms constraining BP180 protein expression to the basal surface of cells of the basal layer, perhaps via complex formation with integrins associated with the hemidesmosome. 22, 23 While retroviral LTR elements can express certain target genes in all layers of stratified epithelium, 30 however, in the absence of in situ hybridization data we cannot conclude that BP180 mRNA is actually stably expressed throughout the epidermis. These data do suggest, however, that well characterized non-targeted promoters such as the retroviral LTR or endogenous housekeeping gene promoters could be useful in efforts to restore BP180 expression in JEB.
The restoration achieved here and in work with other genodermatoses 26 ,31 defines a gene transfer approach that is generally not durable enough to be immediately applied to humans. Although we have restored BP180 protein expression to JEB skin tissue, restoration of gene expression via the gene transfer approach here has been observed to be lost over the course of a month. 26, 32, 33 This loss appears to be due to promoter inactivation rather than death of genetically engineered cells. 30 This work, by demonstrating the first restoration of gene expression in non-immortalized JEB skin tissue in vivo, thus represents a discrete advance in efforts to develop ex vivo gene therapy for JEB. Before application to humans, however, extensive efforts will be required to develop a refined model of corrective gene delivery meeting key additional criteria, such as sustainability. New vectors designed to overcome this problem show promise in this regard and may support gene delivery in human skin through multiple epidermal turnover cycles. 30 These vectors offer hope for future efforts to achieve long-lasting therapeutic gene delivery in JEB gene transfer models as a step before human trials. Generation of this model of gene transfer in human JEB offers a next step in the pathway to developing rational corrective genetic therapies for EB and other human genetic skin disorders.
Materials and methods
JEB patients, cells and cell culture JEB patients were characterized as having junctional EB on the basis of previously published criteria.
1 These included the clinical presence of a congenital mechanobullous eruption in a generalized distribution that led to atrophic scars, a lack of internal organ involvement and evidence of a subepidermal split on histologic examination. In addition, JEB patient skin in the two unrelated Caucasian patients studied here, was characterized as lacking BP180 expression but demonstrated normal levels of expression of other basement membrane zone components implicated in EB, including laminin 5 chains, ␣6␤4 integrins and type VII collagen. Normal control keratinocytes were obtained from unrelated individuals unaffected by EB and without evidence of any other skin disease. Biopsies were obtained in accordance with Stanford IRB approved protocols and early passage keratinocytes were grown as previously described. 34, 35 Amphotropic retroviral expression vector for human BP180 A 4751 bp HindIII/XhoI fragment corresponding to the full length human BP180 cDNA 20 minus 3' polyadenylation sequences was subcloned into the HindIII and SalI sites of the MFG based episomal expression vector LZRS 36 and amphotropic retrovirus produced as previously described.
35
BP180 gene transfer to JEB cells Retroviral transduction of BP180 cells was performed as previously described. 35 Briefly, 5 × 10 4 primary keratinocytes were seeded per 35-mm well and incubated for 12-24 h. Cells were pre-incubated in 2.5 ml of SFM/154 media with 5 g/ml polybrene for 5 min, followed by addition of 2.5 ml thawed viral supernatant supplemented to 5 g/ml polybrene. Plates were centrifuged at 300 g for 1 h at 32°C. The medium was then aspirated from wells, after which 3 ml fresh SFM/154 media was added for cell recovery and further growth in vitro.
BP180 gene expression analysis
For immunoblotting, keratinocyte cell extracts were prepared 35 and 20 g of extract protein electrophoresed on an 8% denaturing polyacrylamide gel before gene transfer and blotting with antibodies to BP180. Both monoclonal 37 and rabbit polyclonal 38 anti-BP180 antibodies were used. Antibodies to BRG1, a constitutively expressed protein, 39 was used as an internal control to verify equivalence of extract quality and protein transfer between samples. Biopsy specimens were obtained from regenerated skin xenografts at 4 weeks after the operation. Frozen tissue skin sections were obtained in stepwise fashion through each tissue block. Sections were then fixed in acetone at room temperature and incubated with antibody to BP180 noted above 37 or to a monoclonal antibody to laminin 5␤3 chain 40 followed by a fluorescein-labeled secondary antibody (Sigma, St Louis, MO, USA) before analysis. Immunofluorescence and immunoblot analysis was performed as previously described. 40 Production of engineered JEB skin in vivo Human JEB and control epidermis 1.5 × 1.5 cm in size was regenerated on immune-deficient SCID mice from cells grown in vitro as previously described. 25, 26 Five mice were grafted for each of the following: normal keratinocytes, untransduced JEB keratinocytes and BP180-transduced JEB keratinocytes.
